Mechanisms of NIrp3 inflammasome activation by mitochondrial dysfunction

线粒体功能障碍激活 NIrp3 炎症小体的机制

基本信息

  • 批准号:
    9392881
  • 负责人:
  • 金额:
    $ 43.75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-12-01 至 2018-11-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The Nlrp3 inflammasome has been linked to both protective and pathologic immune responses. Its appropriate activation triggers the innate immune response to invading pathogens including influenza virus, Staphylococcus aureus and Candida albicans and its excessive response underlies the autoinflammatory syndromes CAPS (cryopyrin associated periodic syndromes). The Nlrp3 inflammasome is also triggered by abnormal metabolic conditions that lead to the development of common debilitating disorders such as gout, type II diabetes mellitus and atherosclerosis. We have identified a novel step in the pathway by which the Nlrp3 inflammasome is activated that reveals a previously unrecognized overlap with the activation of extrinsic apoptotic pathways. Preliminary studies in our lab show that similar to these apoptotic pathways Nlrp3 inflammasome activation induces mitochondrial dysfunction as demonstrated by a loss of the normal negative potential within the mitochondria. During apoptosis this loss of mitochondrial membrane potential is associated with the translocation of the mitochondrial lipid cardiolipin from its location on the inner mitochondril membrane to the outer membrane. This movement is accompanied by oxidation of cardiolipin and the release of its binding partner, cytochrome c, to the intermembrane space. Cardiolipin on the outer mitochondrial membrane recruits and binds caspase-8 that in turn drives the generation of an outer mitochondrial membrane pore through which cytochrome c, loose from its tether to cardiolipin, crosses to the cytosol and triggers immunologically silent cell death by apoptosis. We now show this requirement for and ability to bind mitochondrial cardiolipin is shared by Nlrp3, previously shown to migrate to the mitochondria during activation. Additionally, the loss of mitochondrial membrane potential, a defining step in apoptosis, is also required for Nlrp3 inflammasome activation. In this proposal we specifically dissect the role of cardiolipin in Nlrp3 activation and determine to what extent Nlrp3 inflammasome activation mirrors apoptosis. These studies will determine the point of divergence of these two pathways, important not only to advance our understanding of this vital inflammatory pathway but also because once identified this switch between pathways may prove to be a target for therapeutic intervention. Manipulation of these pathways is attractive not only for modifying Nlrp3 responses but also for the potential to switch from the apoptotic pathway to an inflammatory one as could be of benefit in the setting of malignancy or covert infections.
描述(由申请人提供):Nlrp3炎性小体与保护性和病理性免疫反应有关。它的适当激活会触发对入侵病原体(包括流感病毒、金黄色葡萄球菌和白色念珠菌)的先天免疫反应,其过度反应是自身炎症综合征CAPS (crypyrin相关周期性综合征)的基础。Nlrp3炎症小体也可由代谢异常触发,导致痛风、II型糖尿病和动脉粥样硬化等常见衰弱性疾病的发展。我们已经确定了Nlrp3炎性体激活途径中的一个新步骤,揭示了以前未被认识到的与外源性凋亡途径激活的重叠。我们实验室的初步研究表明,与这些凋亡途径类似,Nlrp3炎性体激活诱导线粒体功能障碍,这可以通过线粒体内正常负电位的丧失来证明。在细胞凋亡过程中,线粒体膜电位的丧失与线粒体脂质心磷脂从线粒体内膜到外膜的易位有关。这种运动伴随着心磷脂的氧化及其结合伙伴细胞色素c向膜间空间的释放。线粒体外膜上的心磷脂招募并结合caspase-8, caspase-8反过来驱动线粒体外膜孔的产生,细胞色素c从心磷脂的束缚中解脱出来,通过这个孔进入细胞质,触发免疫沉默细胞死亡

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Mitochondria in innate immune signaling.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SUZANNE L. CASSEL其他文献

SUZANNE L. CASSEL的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SUZANNE L. CASSEL', 18)}}的其他基金

Innate NLRC4 signaling controls adaptive immune responses
先天 NLRC4 信号控制适应性免疫反应
  • 批准号:
    10707832
  • 财政年份:
    2023
  • 资助金额:
    $ 43.75万
  • 项目类别:
Mechanism of Nlrp3 inflammasome activation by mitochondrial dysfunction
线粒体功能障碍激活Nlrp3炎症小体的机制
  • 批准号:
    8773574
  • 财政年份:
    2013
  • 资助金额:
    $ 43.75万
  • 项目类别:
Mechanism of Nlrp3 inflammasome activation by mitochondrial dysfunction
线粒体功能障碍激活Nlrp3炎症小体的机制
  • 批准号:
    8628607
  • 财政年份:
    2013
  • 资助金额:
    $ 43.75万
  • 项目类别:
Role of Lung Inflammation in Th2 Priming
肺部炎症在 Th2 启动中的作用
  • 批准号:
    7640840
  • 财政年份:
    2007
  • 资助金额:
    $ 43.75万
  • 项目类别:
Role of Lung Inflammation in Th2 Priming
肺部炎症在 Th2 启动中的作用
  • 批准号:
    7673404
  • 财政年份:
    2007
  • 资助金额:
    $ 43.75万
  • 项目类别:
Role of Lung Inflammation in Th2 Priming
肺部炎症在 Th2 启动中的作用
  • 批准号:
    8048013
  • 财政年份:
    2007
  • 资助金额:
    $ 43.75万
  • 项目类别:
Role of Lung Inflammation in Th2 Priming
肺部炎症在 Th2 启动中的作用
  • 批准号:
    7208248
  • 财政年份:
    2007
  • 资助金额:
    $ 43.75万
  • 项目类别:
Role of Lung Inflammation in Th2 Priming
肺部炎症在 Th2 启动中的作用
  • 批准号:
    7763792
  • 财政年份:
    2007
  • 资助金额:
    $ 43.75万
  • 项目类别:
Role of Lung Inflammation in Th2 Priming
肺部炎症在 Th2 启动中的作用
  • 批准号:
    7348376
  • 财政年份:
    2007
  • 资助金额:
    $ 43.75万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 43.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 43.75万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 43.75万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 43.75万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 43.75万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 43.75万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 43.75万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 43.75万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 43.75万
  • 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
  • 批准号:
    23K05057
  • 财政年份:
    2023
  • 资助金额:
    $ 43.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了